Instadose Pharma (Instadose Pharma) Debt-to-Equity : 0.01 (As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Debt-to-Equity?

Instadose Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2022 was $0.12 Mil. Instadose Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2022 was $0.07 Mil. Instadose Pharma's Total Stockholders Equity for the quarter that ended in Feb. 2022 was $28.05 Mil. Instadose Pharma's debt to equity for the quarter that ended in Feb. 2022 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Instadose Pharma's Debt-to-Equity or its related term are showing as below:

INSD's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Instadose Pharma Debt-to-Equity Historical Data

The historical data trend for Instadose Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Debt-to-Equity Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Debt-to-Equity

Get a 7-Day Free Trial

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	0.01

Competitive Comparison of Instadose Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instadose Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's Debt-to-Equity falls into.

Instadose Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Instadose Pharma's Debt to Equity Ratio for the fiscal year that ended in Nov. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.165
	=	0.00

Instadose Pharma's Debt to Equity Ratio for the quarter that ended in Feb. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.123	+	0.065)	/	28.053
	=	0.01

Instadose Pharma (OTCPK:INSD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Instadose Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.